Fact Sheet: President Donald J. Trump Announces Expansion of TrumpRx.gov to Bring Americans Transparency and Choice on Everyday Medicines

President Donald J. Trump has announced a major expansion of TrumpRx.gov, transforming the platform into a centralized hub for price transparency and competition for generic medications. This move is designed to help millions of Americans bypass "insurance middlemen" to access the lowest possible cash prices for their daily prescriptions.

Here is a summary of the new features and the administration’s progress on lowering healthcare costs:

Starting today, TrumpRx.gov features more than 600 generic medications, including common treatments for cholesterol (atorvastatin), high blood pressure (lisinopril), and diabetes (metformin).

• • Price Comparison Tool: Patients can now see the most competitive cash prices for their medications and compare them directly against the co-pays offered by their insurance companies.

  • Private Sector Integration: The platform now integrates real-time discounts and delivery options from major private providers, including Amazon Pharmacy, Cost Plus Drugs, and GoodRx.

  • User Choice: By listing these discounts in one place, the administration aims to drive aggressive price competition among the nation’s largest pharmacy discount companies.

The administration clarified that these generic savings are a separate pillar of the TrumpRx platform:

• • Branded Drugs: The site continues to provide access to the deep discounts on high-cost branded medications negotiated through the President’s Most-Favored-Nation (MFN) agreements.

  • Generics: The new 600+ listings focus on everyday, off-patent medications that are commonly used by the general population.

  • Note: The platform does not offer controlled substances or drugs requiring FDA-mandated risk mitigation strategies.

The President framed this expansion as a fulfillment of his promise to ensure Americans no longer pay high prices to "subsidize" low prices in the rest of the world.

• • MFN Milestone: Since 2025, the President has secured 17 deals with major manufacturers, representing the vast majority of the branded drug market, to align U.S. prices with the lowest international rates.

  • International Reciprocity: The administration highlighted its agreement with the United Kingdom, which increased drug prices in the U.K. by 25% to ensure foreign nations pay their fair share for American-led medical innovation.

Building on the launch of TrumpRx.gov, the President is calling on Congress to pass The Great Healthcare Plan. This legislation would:

• • Codify MFN savings into federal law to make them permanent.

  • Lower insurance premiums and hold providers accountable.

  • Maximize price transparency across the entire healthcare system.

Conclusion:
By providing a direct-to-consumer platform that bypasses traditional insurance complexities, the administration aims to put "patients over profits." President Trump characterized today’s announcement as a historic innovation that makes the drug-purchasing process simple, transparent, and competitive for every American family.